Virus-Free and Live-Cell Visualizing SARS-CoV-2 Cell Entry for Studies of Neutralizing Antibodies and Compound Inhibitors
The continued corona virus illness 2019 (COVID-19) pandemic, brought on by SARS-CoV-2 an infection, has resulted in a whole bunch of hundreds of deaths. Mobile entry of SARS-CoV-2, which is mediated by the viral spike protein and ACE2 receptor, is a necessary goal for the event of vaccines, therapeutic antibodies, and medicines. Utilizing a mammalian cell expression system, a genetically engineered sensor of fluorescent protein (Gamillus)-fused SARS-CoV-2 spike trimer (STG) to probe the viral entry course of is developed.
In ACE2-expressing cells, it’s discovered that the STG probe has glorious efficiency within the live-cell visualization of receptor binding, mobile uptake, and intracellular trafficking of SARS-CoV-2 underneath virus-free situations. The brand new system permits quantitative analyses of the inhibition potentials and detailed affect of COVID-19-convalescent human plasmas, neutralizing antibodies and compounds, offering a flexible software for high-throughput screening and phenotypic characterization of SARS-CoV-2 entry inhibitors. This strategy might also be tailored to develop a viral entry visualization system for different viruses.
The position of therapeutic plasma trade in clinically amyopathic dermatomyositis with MDA-5 antibody: A case report and assessment of the literature
Clinically amyopathic dermatomyositis (CADM) is a uncommon, aggressive variant of dermatomyositis related to interstitial lung illness (ILD) and refractoriness to immunosuppressants. Antibodies towards melanoma differentiation-associated gene 5 (MDA-5) are sometimes present in sufferers with CADM. We report a affected person with superior CADM with ILD and MDA-5 antibodies who failed to enhance with immunosuppressants. We carried out 2 TPE over three days, utilizing 5% albumin as alternative fluid.
Though 5 complete TPE had been deliberate, he was transferred for lung transplant analysis after the second TPE; he died 16 days after switch with out receiving a transplant. A literature assessment recognized 4 sufferers with CADM and MDA-5 antibodies handled with TPE; all skilled symptomatic enchancment of their ILD. We attribute our affected person’s final result to the superior nature of his illness quite than a failure of TPE. Further analysis could point out a attainable reclassification of CADM with MDA-5 antibodies in future ASFA tips.
Chemical Conjugation of a Purified DEC-205-Directed Antibody with Full-Size Protein for Concentrating on Mouse Dendritic Cells In Vitro and In Vivo
Focused antigen supply to cross-presenting dendritic cells (DC) in vivo effectively induces T effector cell responses and shows a beneficial strategy in vaccine design. Antigen is delivered to DC by way of antibodies particular for endocytosis receptors corresponding to DEC-205 that induce uptake, processing, and MHC class I- and II-presentation. Environment friendly and dependable conjugation of the specified antigen to an acceptable antibody is a essential step in DC concentrating on and amongst different components is determined by the format of the antigen. Chemical conjugation of full-length protein to purified antibodies is one attainable technique. Prior to now, we have now efficiently established cross-linking of the mannequin antigen ovalbumin (OVA) and a DEC-205-specific IgG2a antibody (αDEC-205) for in vivo DC concentrating on research in mice.
Step one of the protocol is the purification of the antibody from the supernatant of the NLDC (non-lymphoid dendritic cells)-145 hybridoma by affinity chromatography. The purified antibody is activated for chemical conjugation by sulfo-SMCC (sulfosuccinimidyl 4-[N-maleimidomethyl] cyclohexane-1-carboxylate) whereas on the similar time the sulfhydryl-groups of the OVA protein are uncovered via incubation with TCEP-HCl (tris (2-carboxyethyl) phosphine hydrochloride).
Extra TCEP-HCl and sulfo-SMCC are eliminated and the antigen is combined with the activated antibody for in a single day coupling. The ensuing αDEC-205/OVA conjugate is concentrated and free of unbound OVA. Profitable conjugation of OVA to αDEC-205 is verified by western blot evaluation and enzyme-linked immunosorbent assay (ELISA). We’ve got efficiently used chemically crosslinked αDEC-205/OVA to induce cytotoxic T cell responses within the liver and to check completely different adjuvants for his or her potential in inducing humoral and mobile immunity following in vivo concentrating on of DEC-205+ DC.
Past that, such chemically coupled antibody/antigen conjugates provide beneficial instruments for the environment friendly induction of vaccine responses to tumor antigens and have been confirmed to be superior to classical immunization approaches relating to the prevention and remedy of assorted varieties of tumors.
Excessive seroprevalence of anti-Fasciola antibody amongst cattle farm staff and dwellers in Kelantan
Human fascioliasis is a public well being drawback significantly in areas the place ruminants are raised. The goals of this research had been to find out the seroprevalence of anti-Fasciola antibody and the related danger components amongst cattle farm staff and dwellers in Kelantan.
A complete of 90 blood samples had been collected on this cross-sectional research. A set of validated questionnaire was used to acquire data on socio-demographic profiles and dietary habits of members. The sera had been subjected to enzyme linked immunosorbent assay (ELISA) for the detection of anti-Fasciola IgG antibody. The affiliation between seropositivity and the numerous danger components had been decided by way of logistic regression. From the consequence, serological screening revealed 60 (67%) members optimistic for anti-Fasciola IgG antibody.
Recombinant Mouse VEGF-A/VEGF164 |
CX73-10ug |
Novoprotein |
10ug |
EUR 242.4 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
Recombinant Mouse VEGF-A/VEGF164 |
CX73-1mg |
Novoprotein |
1mg |
EUR 2983.2 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
Recombinant Mouse VEGF-A/VEGF164 |
CX73-500ug |
Novoprotein |
500ug |
EUR 1935.6 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
Recombinant Mouse VEGF-A/VEGF164 |
CX73-50ug |
Novoprotein |
50ug |
EUR 595.2 |
Description: Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4. |
Recombinant Mouse VEGF-A/VEGF164 |
AP75658 |
SAB |
1mg |
EUR 3489 |
|
Anti-Mouse VEGF-A Antibody |
103-M57 |
ReliaTech |
100 µg |
EUR 399 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Mouse VEGF-A Antibody |
103-M57A |
ReliaTech |
100 µg |
EUR 399 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Mouse VEGF-A Antibody |
103-P36 |
ReliaTech |
100 µg |
EUR 245.7 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Mouse VEGF-A Antibody |
103-PA03 |
ReliaTech |
200 µg |
EUR 246.75 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Mouse VEGF-A Antibody |
103-PABi03 |
ReliaTech |
50 µg |
EUR 157.5 |
Description: Mouse VEGF is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothelial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase (flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant murine VEGF (isoform 164) is a 39.0 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Recombinant Mouse VEGF-A/VEGF164 Protein |
PKSM041180-10ug |
Elabscience Biotech |
10ug |
EUR 178 |
|
Description: Mouse |
Recombinant Mouse VEGF-A/VEGF164 Protein |
PKSM041180-50ug |
Elabscience Biotech |
50ug |
EUR 523 |
|
Description: Mouse |
VEGF-A(VEGF/1063) Antibody |
BNC811063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC811063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC801063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC801063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF680 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC431063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC431063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF543 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC051063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC051063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF405M conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC551063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC551063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF555 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC701063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC701063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF770 conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC611063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNC611063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), CF660R conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNCP1063-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), PerCP conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNCR1063-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), RPE conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNCA1063-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against VEGF-A(VEGF/1063), APC conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNCH1063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNCH1063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNCAP1063-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
VEGF-A(VEGF/1063) Antibody |
BNCAP1063-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against VEGF-A(VEGF/1063), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Mouse VEGF-A Recombinant Protein |
R00045-4 |
BosterBio |
5ug/vial |
EUR 310.8 |
Description: VEGF-A is member of the family of vascular endothelial growth factor (VEGF) proteins, which stimulate vasculogenesis and angiogenesis to restore oxygen supply to tissues. VEGF-A is also a vasodilator and increases microvascular permeability and was originally referred to as vascular permeability factor (VPF). Mouse VEGF-A Recombinant Protein is purified vascular endothelial growth factor A produced in yeast. |
mouse anti-human VEGF mAb |
E409C31-m100 |
EnoGene |
100μL |
EUR 395 |
Description: Available in various conjugation types. |
Active Recombinant Mouse VEGF-A/VEGF164 Protein |
RP01060 |
Abclonal |
10 μg |
EUR 130 |
|
Mouse Monoclonal anti-human VEGF-165b |
hAP-0051 |
Angio Proteomie |
100ug |
EUR 250 |
Anti-Rat VEGF-A Antibody |
104-P15 |
ReliaTech |
100 µg |
EUR 245.7 |
Description: Rat VEGF (or VEGF-A) is a potent growth and angiogenic cytokine. It stimulates proliferation and survival of endothellial cells, and promotes angiogenesis and vascular permeability. Expressed in vascularized tissues, VEGF plays a prominent role in normal and pathological angiogenesis. Substantial evidence implicates VEGF in the induction of tumor metastasis and intra-ocular neovascular syndromes. VEGF signals through the three receptors; fms-like tyrosine kinase(flt-1), KDR gene product (the murine homolog of KDR is the flk-1 gene product) and the flt4 gene product. Recombinant rat VEGF (isoform 164) is a 38.5 kDa disulfide-linked homodimeric protein consisting of two 164 amino acid polypeptide chains. |
Anti-Human VEGF-A Antibody |
101-M57 |
ReliaTech |
100 µg |
EUR 399 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody |
101-M60 |
ReliaTech |
100 µg |
EUR 173.25 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody |
101-M855 |
ReliaTech |
100 µg |
EUR 399 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody |
101-MBi60 |
ReliaTech |
50 µg |
EUR 173.25 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody |
102-P91 |
ReliaTech |
100 µg |
EUR 245.7 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody |
102-P91G |
ReliaTech |
100 µg |
EUR 245.7 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. In cultured endothelial cells, VEGF can activate phospholipase C and induce rapid increases of free cytosolic Ca2+. VEGF has also been shown to be chemotactic for monocytes and osteoblasts. In vivo, VEGF can induce angiogenesis as well as increase microvascular permeability. As a vascular permeability factor, VEGF acts directly on the endothelium and does not degranulate mast cells. Based on its in vitro and in vivo properties, VEGF is expected to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. |
Anti-Human VEGF-A Antibody |
102-PA02 |
ReliaTech |
200 µg |
EUR 147 |
Description: Vascular endothelial growth factor (VEGF or VEGF-A), also known as vascular permeability factor (VPF) or vasculotropin, is a homodimeric 34 - 42 kDa, heparin-binding glycoprotein with potent angiogenic, mitogenic and vascular permeability-enhancing activities specific for endothelial cells. Different isoforms can be generated by differential splicing (e.g. VEGF165). All eight cysteine residues involved in intra- and inter-chain disulfide bonds are conserved among these growth factors. A cDNA encoding a protein having a 53% amino acid sequence homology in the PDGF-like region of VEGF has been isolated from a human placental cDNA library. This protein, named placenta growth factor (PlGF), is now recognized to be a member of the VEGF family of growth factors. Two receptor tyrosine kinases have been described as putative VEGF receptors. Flt-1 (fms-like tyrosine kinase), and KDR (kinase-insert-domain-containing receptor) proteins have been shown to bind VEGF-A with high affinity. In vitro, VEGF is a potent endothelial cell mitogen. The antibody is against the N-terminus and will recognize all VEGF-A isoforms. |
Rat Monoclonal anti-Mouse VEGF-A Antibody |
xAP-0835 |
Angio Proteomie |
100ug |
EUR 280 |
Mouse Monoclonal anti-Human VEGF Antibody |
xAP-0471 |
Angio Proteomie |
100ug |
EUR 280 |
Recombinant Mouse VEGF (121 a. a. ) Protein, Untagged, E.coli-1mg |
QP13933-1mg |
EnQuireBio |
1mg |
EUR 4287.6 |
Recombinant Mouse VEGF (121 a. a. ) Protein, Untagged, E.coli-2ug |
QP13933-2ug |
EnQuireBio |
2ug |
EUR 186 |
Recombinant Mouse VEGF (121 a. a. ) Protein, Untagged, E.coli-10ug |
QP13933-10ug |
EnQuireBio |
10ug |
EUR 241.2 |
VEGF-A(VEGF/1063), 0.2mg/mL |
BNUB1063-100 |
Biotium |
100uL |
EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
VEGF-A(VEGF/1063), 0.2mg/mL |
BNUB1063-500 |
Biotium |
500uL |
EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
VEGF-A(VEGF/1063), 1mg/mL |
BNUM1063-50 |
Biotium |
50uL |
EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
VEGF-A Antibody |
F41972-0.08ML |
NSJ Bioreagents |
0.08 ml |
EUR 140.25 |
|
Description: This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. |
VEGF-A Antibody |
F41972-0.4ML |
NSJ Bioreagents |
0.4 ml |
EUR 322.15 |
|
Description: This gene is a member of the PDGF/VEGF growth factor family and encodes a protein that is often found as a disulfide linked homodimer. This protein is a glycosylated mitogen that specifically acts on endothelial cells and has various effects, including mediating increased vascular permeability, inducing angiogenesis, vasculogenesis and endothelial cell growth, promoting cell migration, and inhibiting apoptosis. Elevated levels of this protein is linked to POEMS syndrome, also known as Crow-Fukase syndrome. Mutations in this gene have been associated with proliferative and nonproliferative diabetic retinopathy. Alternatively spliced transcript variants, encoding either freely secreted or cell-associated isoforms, have been characterized. There is also evidence for the use of non-AUG (CUG) translation initiation sites upstream of, and in-frame with the first AUG, leading to additional isoforms. |
Mouse Monoclonal anti-human VEGF-B 167 |
hAP-0008 |
Angio Proteomie |
100ug |
EUR 250 |
Mouse Monoclonal anti-human VEGF-B 167 |
hAP-0008A |
Angio Proteomie |
100ug |
EUR 250 |
Mouse Monoclonal anti-human VEGF-B 186 |
hAP-1122 |
Angio Proteomie |
100ug |
EUR 250 |
Mouse Monoclonal anti-human VEGF-B 186 |
hAP-1122A |
Angio Proteomie |
100ug |
EUR 250 |
Biotinylated Anti-bovine VEGF-A PAb |
GWB-USW6N4 |
GenWay Biotech |
1 kit |
Ask for price |
Biotinylated Anti-equine VEGF-A PAb |
GWB-KI0045 |
GenWay Biotech |
1 kit |
Ask for price |
Mouse VEGF Antibody (Biotin) |
GWB-8C659A |
GenWay Biotech |
0.05 mg |
Ask for price |
Mouse Recombinant VEGF164 (VEGF-A) Protein (Sf9), biologically active |
VEGF34-R-10 |
Alpha Diagnostics |
10 ug |
EUR 534 |
Mouse Recombinant VEGF164 (VEGF-A) Protein (Sf9), biologically active |
VEGF34-R-100 |
Alpha Diagnostics |
100 ug |
EUR 2973.6 |
Mouse Recombinant VEGF165 (VEGF-A) Protein (E.Coli), biologically active |
VEGF35-R-10 |
Alpha Diagnostics |
10 ug |
EUR 534 |
Mouse Recombinant VEGF165 (VEGF-A) Protein (E.Coli), biologically active |
VEGF35-R-100 |
Alpha Diagnostics |
100 ug |
EUR 2690.4 |
VEGF Mouse mAb |
A17877-100ul |
Abclonal |
100 ul |
EUR 460.8 |
VEGF Mouse mAb |
A17877-200ul |
Abclonal |
200 ul |
EUR 664.8 |
VEGF Mouse mAb |
A17877-20ul |
Abclonal |
20 ul |
EUR 265.2 |
VEGF Mouse mAb |
A17877-50ul |
Abclonal |
50 ul |
EUR 318 |
Recombinant Mouse VEGF 164 |
EPT170 |
ELK Biotech |
10ug |
EUR 167.4 |
|
Description: Recombinant Mouse Vascular Endothelial Growth Factor A is produced by our Yeast expression system and the target gene encoding Ala27-Arg190 is expressed. |
Recombinant Mouse VEGF (164aa) |
Z200575 |
ABM |
10 µg |
EUR 50 |
Description: VEGF is a homodimeric heavily glycosylated protein. The human factor occurs in several molecular variants of 120, 162, 145, 148, 164, 183, 189, 206 amino acids, arising by alternative splicing of the mRNA. The splice forms of VEGF differ in biological properties such as the receptor types, which they recognize and their interaction with heparan sulfate proteoglycans. The 165 amino acid form of the factor is the most common form in most tissues. Kaposi sarcomas express VEGF121 and VEGF165. VEGF121 and VEGF165 are soluble secreted forms of the factor while VEGF189 and VEGF206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. A high-affinity glycoprotein receptor of 170-235 kDa is expressed on vascular endothelial cells. The interaction of VEGF with heparin-like molecules of the extracellular matrix is required for efficient receptor binding. Protamine sulfate and suramin are capable of replacing the receptor-bound factor. The high-affinity receptor for VEGF, now known as VEGFR1, has been identified as the gene product of the FLT-1. Another receptor for VEGF, now known as VEGFR2, is KDR, also known as FLK-1. A factor that competes with the 165 amino acid form of VEGF for receptor binding is PLGF. A third receptor type, VEGFR3 is known also as FLT-4. An isoform-specific receptor for VEGF165 has been identified as human Neuropilin-1. |
Recombinant Mouse VEGF (164aa) |
Z200577 |
ABM |
100 µg |
EUR 450 |
Description: VEGF is a homodimeric heavily glycosylated protein. The human factor occurs in several molecular variants of 120, 162, 145, 148, 164, 183, 189, 206 amino acids, arising by alternative splicing of the mRNA. The splice forms of VEGF differ in biological properties such as the receptor types, which they recognize and their interaction with heparan sulfate proteoglycans. The 165 amino acid form of the factor is the most common form in most tissues. Kaposi sarcomas express VEGF121 and VEGF165. VEGF121 and VEGF165 are soluble secreted forms of the factor while VEGF189 and VEGF206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. A high-affinity glycoprotein receptor of 170-235 kDa is expressed on vascular endothelial cells. The interaction of VEGF with heparin-like molecules of the extracellular matrix is required for efficient receptor binding. Protamine sulfate and suramin are capable of replacing the receptor-bound factor. The high-affinity receptor for VEGF, now known as VEGFR1, has been identified as the gene product of the FLT-1. Another receptor for VEGF, now known as VEGFR2, is KDR, also known as FLK-1. A factor that competes with the 165 amino acid form of VEGF for receptor binding is PLGF. A third receptor type, VEGFR3 is known also as FLT-4. An isoform-specific receptor for VEGF165 has been identified as human Neuropilin-1. |
Recombinant Mouse VEGF (164aa) |
Z200579 |
ABM |
1.0 mg |
EUR 1500 |
Description: VEGF is a homodimeric heavily glycosylated protein. The human factor occurs in several molecular variants of 120, 162, 145, 148, 164, 183, 189, 206 amino acids, arising by alternative splicing of the mRNA. The splice forms of VEGF differ in biological properties such as the receptor types, which they recognize and their interaction with heparan sulfate proteoglycans. The 165 amino acid form of the factor is the most common form in most tissues. Kaposi sarcomas express VEGF121 and VEGF165. VEGF121 and VEGF165 are soluble secreted forms of the factor while VEGF189 and VEGF206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. A high-affinity glycoprotein receptor of 170-235 kDa is expressed on vascular endothelial cells. The interaction of VEGF with heparin-like molecules of the extracellular matrix is required for efficient receptor binding. Protamine sulfate and suramin are capable of replacing the receptor-bound factor. The high-affinity receptor for VEGF, now known as VEGFR1, has been identified as the gene product of the FLT-1. Another receptor for VEGF, now known as VEGFR2, is KDR, also known as FLK-1. A factor that competes with the 165 amino acid form of VEGF for receptor binding is PLGF. A third receptor type, VEGFR3 is known also as FLT-4. An isoform-specific receptor for VEGF165 has been identified as human Neuropilin-1. |
Recombinant Mouse VEGF (120aa) |
Z200585 |
ABM |
10 µg |
EUR 85 |
Description: VEGF is a homodimeric heavily glycosylated protein. The human factor occurs in several molecular variants of 120, 162, 145, 148, 164, 183, 189, 206 amino acids, arising by alternative splicing of the mRNA. The splice forms of VEGF differ in biological properties such as the receptor types, which they recognize and their interaction with heparan sulfate proteoglycans. The 165 amino acid form of the factor is the most common form in most tissues. Kaposi sarcomas express VEGF121 and VEGF165. VEGF121 and VEGF165 are soluble secreted forms of the factor while VEGF189 and VEGF206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. A high-affinity glycoprotein receptor of 170-235 kDa is expressed on vascular endothelial cells. The interaction of VEGF with heparin-like molecules of the extracellular matrix is required for efficient receptor binding. Protamine sulfate and suramin are capable of replacing the receptor-bound factor. The high-affinity receptor for VEGF, now known as VEGFR1, has been identified as the gene product of the FLT-1. Another receptor for VEGF, now known as VEGFR2, is KDR, also known as FLK-1. A factor that competes with the 165 amino acid form of VEGF for receptor binding is PLGF. A third receptor type, VEGFR3 is known also as FLT-4. An isoform-specific receptor for VEGF165 has been identified as human Neuropilin-1. |
Recombinant Mouse VEGF (120aa) |
Z200587 |
ABM |
100 µg |
EUR 480 |
Description: VEGF is a homodimeric heavily glycosylated protein. The human factor occurs in several molecular variants of 120, 162, 145, 148, 164, 183, 189, 206 amino acids, arising by alternative splicing of the mRNA. The splice forms of VEGF differ in biological properties such as the receptor types, which they recognize and their interaction with heparan sulfate proteoglycans. The 165 amino acid form of the factor is the most common form in most tissues. Kaposi sarcomas express VEGF121 and VEGF165. VEGF121 and VEGF165 are soluble secreted forms of the factor while VEGF189 and VEGF206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. A high-affinity glycoprotein receptor of 170-235 kDa is expressed on vascular endothelial cells. The interaction of VEGF with heparin-like molecules of the extracellular matrix is required for efficient receptor binding. Protamine sulfate and suramin are capable of replacing the receptor-bound factor. The high-affinity receptor for VEGF, now known as VEGFR1, has been identified as the gene product of the FLT-1. Another receptor for VEGF, now known as VEGFR2, is KDR, also known as FLK-1. A factor that competes with the 165 amino acid form of VEGF for receptor binding is PLGF. A third receptor type, VEGFR3 is known also as FLT-4. An isoform-specific receptor for VEGF165 has been identified as human Neuropilin-1. |
Recombinant Mouse VEGF (120aa) |
Z200589 |
ABM |
1.0 mg |
EUR 2150 |
Description: VEGF is a heavily glycosylated, homodimeric protein. The human factor occurs in several molecular variants of 120, 162, 145, 148, 164, 183, 189, 206 amino acids, arising by alternative splicing of the mRNA. The splice forms of VEGF differ in biological properties such as the receptor types, which they recognize and their interaction with heparan sulfate proteoglycans. The 165 amino acid form of the factor is the most common form in most tissues. Kaposi sarcomas express VEGF121 and VEGF165. VEGF121 and VEGF165 are soluble secreted forms of the factor while VEGF189 and VEGF206 are mostly bound to heparin-containing proteoglycans in the cell surface or in the basement membrane. A high-affinity glycoprotein receptor of 170-235 kDa is expressed on vascular endothelial cells. The interaction of VEGF with heparin-like molecules of the extracellular matrix is required for efficient receptor binding. Protamine sulfate and suramin are capable of replacing the receptor-bound factor. The high-affinity receptor for VEGF, now known as VEGFR1, has been identified as the gene product of the FLT-1. Another receptor for VEGF, now known as VEGFR2, is KDR, also known as FLK-1. A factor that competes with the 165 amino acid form of VEGF for receptor binding is PLGF. A third receptor type, VEGFR3 is known also as FLT-4. An isoform-specific receptor for VEGF165 has been identified as human Neuropilin-1. |
Rat VEGF-A |
91008 |
BPS Bioscience |
10 µg |
EUR 220 |
Description: Recombinant rat vascular endothelial growth factor A (VEGF-A) expressed in E. coli cells. Rat recombinant VEGF-A contains 165 amino acids and has a molecular weight of 38.7 kDa. VEGF is an important growth factor involved in both vasculogenesis and angiogenesis. |
VEGF-A,Swine |
E34M020S |
EnoGene |
5 μg |
EUR 295 |
Mouse VEGF-A Recombinant Protein Tag Free Lyophilized |
IMSVEGFARTFLY50UG |
Innovative research |
each |
EUR 988 |
|
Description: Mouse VEGF-A Recombinant Protein Tag Free Lyophilized |
Mouse Anti Human Vegf Receptor 1 Monoclonal Antibody |
CABT-47861MH |
Creative Diagnostics |
0.1 mg |
EUR 1070.4 |
Mouse Vascular Endothelial Growth Factor A,VEGF- A ELISA Kit |
ELA-E1851m |
Lifescience Market |
96 Tests |
EUR 1038 |
Mouse Vascular Endothelial Growth Factor A (VEGF-A) ELISA Kit |
SL0832Mo |
Sunlong |
- |
Ask for price |
|
Anti-Mouse VEGF-B Antibody |
103-M62 |
ReliaTech |
100 µg |
EUR 399 |
Description: Vascular endothelial growth factor B (VEGF-B), also known as vascular endothelial growth factor-related factor (VRF), is a member of the VEGF family of growth factors that share structural and functional similarity. |
Anti-Mouse VEGF-D Antibody |
103-M66 |
ReliaTech |
100 µg |
EUR 399 |
Description: VEGF-D, a member of the VEGF/PDGF family of structurally related proteins, is a potent angiogenic cytokine. It promotes endothelial cell growth, promotes lymphangiogesis, and can also affect vascular permeability. VEGF-D is highly expressed in the lung, heart, small intestine and fetal lung, and at lower levels in the skeletal muscle, colon, and pancreas. It forms cell surfaced-associated non-covalent disulfide linked homodimers, and can bind and activate both VEGFR-2 (flk1) and VEGFR-3 (flt4) receptors. During embryogenesis, VEGF-D may play a role in the formation of the venous and lymphatic vascular systems. It also participates in the growth and maintenance of differentiated lymphatic endothelium in adults. Both VEGF-C and VEGF-D are over-expressed in certain cancers, and the resulting elevated levels of VEGF-C or VEGF-D tend to correlate with increased lymphatic metastasis. |
Anti-mouse VEGF(Rat) Antibody |
Y052991 |
ABM |
100 µg |
EUR 695 |
The components discovered to be considerably related to seropositivity towards anti-Fasciola IgG antibody had been the age group of 18 years outdated and above with calculated odds ratio of three.2 instances (p=0.032) and the period of farming actions of greater than 5 years with calculated odds ratio of two.6 instances (p=0.036). In conclusion, Fasciola an infection is prevalent amongst cattle farm staff and dwellers in Kelantan.
Tags :
dna,
dna ancestry,
dna block,
dna bts,
dna genetics,
dna hr block,
dna hrblock login,
dna lyrics,
dna motoring,
dna painter,
dna productions,
dna replication,
dna song,
dna study slavery,
dna template sequence,
dna template slippage,
dna template strand,
dna template strand and non-template strand,
dna template strand and rna strand,
dna template strand coding strand,
dna template strand definition,
dna template strand meaning,
dna template strand mrna,
dna template strand read in what direction,
dna template strand role in transcription,
dna template strand sequencing,
dna template strand to amino acid translation,
dna template strand transcription,
dna template strand translation,
exosomes 5g,
exosomes and chf,
exosomes and coronavirus,
exosomes and ed,
exosomes and ms,
exosomes and ra,
exosomes and viruses,
exosomes are virus,
exosomes dr kaufman,
exosomes for delivery,
exosomes for hair,
exosomes for hair loss,
exosomes msc,
exosomes nj,
exosomes tem,
exosomes therapy,
exosomes treatment,
gels iga,
gels iga st henry ohio,
gels kitchen,
gelsemium,
gelsemium homeopathic,
gelsemium sempervirens,
gelsenkirchen,
gelsey kirkland,
gelsey kirkland 2020,
gelsolin,
gelson’s instacart,
gelson’s market